Navigation Links
23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee
Date:1/25/2011

MOUNTAIN VIEW, CA January 25, 2011 23andMe's sarcoma research efforts are well underway with collection of both phenotypic and genetic data from 500 individuals diagnosed with sarcoma already completed. The company is half way towards its goal of building a sarcoma research community of more than 1,000 individuals. 23andMe has also completed its Independent Sarcoma Scientific Advisory Committee with the appointment of leading researchers and clinicians, including Robert Maki, MD, PhD, George Demetri, MD, Judy Garber, MD, MPH, and Mark Robson, MD.

"Members of our independent, external Sarcoma Advisory Committee bring unsurpassed expertise of sarcoma and cancer genetics to our research efforts," said Anne Wojcicki, 23andMe co-founder and CEO. "We are confident that together, we will meaningfully advance our current understanding of sarcomas."

Sarcomas are a rare group of cancers that arise in connective tissues (such as muscle, fat, cartilage, tendons and blood vessels) or in bone. It is estimated that there are approximately 13,000 cases of Sarcoma seen annually in the United States. This is an extremely small number compared to the total of more than 1.4 million people who are diagnosed with cancer each year in the United States. The small number of cases seen, the diversity in the biology of each type of sarcoma, and other variables make identifying and understanding causes of Sarcomas particularly difficult.

23andMe's Sarcoma research efforts first began in April 2010, inviting current and former sarcoma patients to participate by being genotyped and completing surveys about their disease and treatment response through the 23andMe web-based research platform, under approval from an Institutional Review Board (IRB). Participants receive access to the full 23andMe experience, including information about their genetic ancestry as well as access to all 184 health and trait reports at no charge.

As 23andMe collects information regarding these individuals' experience, environment and response to different therapies, it is anticipated that 23andMe will be able to combine this information with genetic data to find patterns that will help researchers better understand the biology of sarcoma and the impact of various treatments.

"We have already enrolled more than 500 individuals diagnosed with Sarcoma, passing the 50-percent milestone in our goal of building a sarcoma community of at least 1,000 individuals. Through our research platform, we are gathering valuable information about sarcoma and response to treatment from these individuals," explained Amy Kiefer, 23andMe, Survey Research Manager, PhD.

"This collaborative project is highly innovative, linking sophisticated genomic analyses with patient-reported outcomes and clinical data in people who have had sarcoma at some point in their lives. It is a novel, multidimensional approach to understanding these complex diseases with a mixture of science, medicine and social media," said George Demetri, MD, Director of the Center for Sarcoma and Bone Oncology at Dana Farber Cancer Institute and Sarcoma Scientific Advisor to 23andMe. "The members of the Sarcoma Scientific Advisory Committee are enthusiastic to advise 23andme to ensure the highest quality data can be generated through this interactive process which brings together current sarcoma patients, long-term survivors of sarcomas, physicians and scientists of several different specialties."


'/>"/>

Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
23andMe Inc.
Source:Eurekalert  

Related biology news :

1. 23andMe presents top 10 most interesting genetic findings of 2010
2. 23andMe receives NIH funding to evaluate web-based research on the genetics of drug response
3. Genetically reprogrammed HSV given systemically shrinks distant sarcomas
4. Potential new drug target to combat Kaposis sarcoma
5. UCSF researchers identify new drug target for Kaposis sarcoma
6. Purdue team creates engineered organ model for breast cancer research
7. Blue crab research may help Chesapeake Bay watermen improve soft shell harvest
8. Research into synthetic antibodies offers hope for new diagnostics
9. ASM Biodefense and Emerging Diseases Research Meeting
10. Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers
11. Climate change threatens many tree species, say Hebrew U. researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/13/2017)... 13, 2017  RSA Conference -- RSA, a Dell ... designed to enhance fraud detection and investigation across ... RSA Fraud & Risk Intelligence Suite. The new ... additional insights from internal and external sources as ... their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... up human tissue regeneration from small lab samples to full-size tissues, bones, even ... to establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... 2017   iSpecimen ®, the marketplace ... Pathology Service (DPS), a full-service anatomic pathology reference ... United States , has joined a program offered ... (DHIN) to make human biospecimens and associated data ... program, announced in 2015 as a collaboration between iSpecimen ...
Breaking Biology Technology: